Prognostic relevance of the mTOR pathway in renal cell carcinoma
Open Access
Abstract
BACKGROUND.: The mammalian target of rapamycin (mTOR) pathway is up‐regulated in many human cancers, and agents targeting the mTOR pathway are in various stages of clinical development. The goal of the study was to evaluate the potential and limitations of targeting the mTOR pathway in renal cell carcinoma (RCC).METHODS.: Immunohistochemical analysis using antibodies against pAkt, PTEN, p27, and pS6 was performed on a tissue microarray constructed from paraffin‐embedded specimens from 375 patients treated by nephrectomy for RCC. The expression was associated with pathological parameters and survival.RESULTS.: The mTOR pathway was more significantly altered in clear‐cell RCC, high‐grade tumors, and tumors with poor prognostic features. PS6 and PTEN showed the strongest associations with pathological parameters. Survival tree analysis regarding expression of cytoplasmic pAkt, nuclear pAkt, PTEN, cytoplasmic p27, and pS6 identified staining percentages of 40%, 10%, 75%, 7%, and 70%, respectively, as ideal cutoff values for stratification, with corresponding P‐values of .03, .001, .02, .005, and <.0001, respectively. Interestingly, high nuclear pAkt expression was associated with a favorable prognosis, whereas high cytoplasmic pAkt expression was associated with a poor prognosis. In multivariate Cox regression analysis, ECOG PS, T classification, N classification, M classification, cytoplasmic Akt, nuclear pAkt, PTEN, and pS6 were independent prognostic factors of DSS.CONCLUSIONS.: Components of the mTOR pathway are significantly associated with pathological features and survival. Not all RCC tumor types seem to be equally amenable to mTOR targeted therapy. PTEN, pAkt, p27, and pS6 may serve as surrogate parameters for patient selection and predicting prognosis. Patients with a highly activated mTOR pathway should benefit most from this therapy. External validation of our results is recommended. Cancer 2007. © 2007 American Cancer Society.Keywords
This publication has 42 references indexed in Scilit:
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2006
- Cancer Statistics, 2006CA: A Cancer Journal for Clinicians, 2006
- Objective Responses in Patients with Malignant Melanoma or Renal Cell Cancer in Early Clinical Studies Do Not Predict Regulatory ApprovalClinical Cancer Research, 2005
- Upstream and downstream of mTORGenes & Development, 2004
- Rheb is a direct target of the tuberous sclerosis tumour suppressor proteinsNature Cell Biology, 2003
- Intragenic PTEN/MMAC1 Loss of Heterozygosity in Conventional (Clear-Cell) Renal Cell Carcinoma is Associated with Poor Patient PrognosisLaboratory Investigation, 2002
- Mathematical Model to Predict Individual Survival for Patients With Renal Cell CarcinomaJournal of Clinical Oncology, 2002
- Tissue microarrays for high-throughput molecular profiling of tumor specimensNature Medicine, 1998
- Cytoplasmic displacement of cyclin E-cdk2 inhibitors p21Cip1 and p27Kip1 in anchorage-independent cellsOncogene, 1998